Eosinophilic Granulomatosis

news

EMA’s human medicines committee (CHMP) September meeting highlights

20 September 2021 | By Anna Begley (European Pharmaceutical Review)

In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.

news

First patients dosed with Fasenra in three dermatology trials

22 April 2021 | By Hannah Balfour (European Pharmaceutical Review)

With the addition of the new dermatology trials, Fasenra is now being evaluated in nine different indications associated with eosinophilic immune dysfunction.

news

FDA approves Nucala for Eosinophilic Granulomatosis with Polyangiitis

15 December 2017 | By Dr Zara Kassam (European Pharmaceutical Review)

The FDA has expanded the approved use of Nucala to treat a rare autoimmune disease that causes vasculitis, an inflammation of the wall of blood vessels of the body...